►
Description
Open project meeting for Open Source Antibiotics Series 1, the Mur Ligases.
Full Project: https://github.com/opensourceantibiotics/murligase
Relevant GitHub Issue: https://github.com/opensourceantibiotics/murligase/issues/75
On the call: Professor Matthew Todd, Dr Edwin Tse, Yuhang Wang, Kato Leonard (UCL), Professor Chris Dowson, Laura Diaz Saez, Adrian Lloyd (University of Warwick), Lizbe Koekemoer (Diamond/Oxford), Dr Lori Ferrins, Dr Joe Eyermann (Northeastern University), Dr Chris Swain (Cambridge MedChem Consulting), Dr Jan Abendroth (UCB Biosciences), Dr Bart Staker (SSGCID).
A
Us
here,
okay,
welcome
everybody
to
open
source
antibiotics
series,
one
the
merlages
is
on
the
10th
of
may
2022,
thanks
very
much
to
chris
for
standing
in
for
me
last
time,
look
like
it
went
well
from
the
recording
and
I
think,
we're
gonna
have
some
more
data
be
presented
on
some
of
the
molecules
that
adrian's
been
looking
at,
which
would
be
great.
I
did
send
him
a
link
to
their
meeting.
A
I
yeah
it
was
interesting
to
hear
about
the
last
time
about
the
ssgcid
and
their
potential
existence
in
the
future.
I
guess
we're
not
quite
yet
sure
jan
do
you
have
any
more
information
about
about
the
future
for,
for
the
group
in
seattle.
A
Yeah
outlook,
I
think
it
it
gets,
is
that
it's
teams,
even
though
I'm
pretty
sure
we
didn't
set
it
up
like
that
yeah
yeah,
you
just
have
to
ignore,
ignore
outlook.
It's
mistaken.
I
just
wonder
if
you
have
any
news
about,
because
I
heard
on
the
last
meeting
that
you
guys
won't
be
able
to
necessarily
contribute
much
after
about
september.
The
1st.
I
just
wonder
if
you
have
any
news
about
ssgcid
and
that
continued
funding
in
existence.
B
I
don't
know
about
the
continuation
of
ssgt.
That's
something
bart
would
be
able
to
answer,
because
it
doesn't
really
impact
me.
Okay,
us
at
all
anymore.
We
are
still
good
to.
I
think.
It's
the
end
of
august,
all
right,
yeah.
A
A
B
A
Yep
got
it
all
right,
while
we're
waiting
for
others
to
join.
Why
don't
we
just
run
through
kayo's,
very
nice
summary
which
she
just
shared.
I
can
share
it
here
if
that
helps
so
keto
has
been
working
on
her
project
in
the
lab
and
is
coming
to
the
end
and
is
going
through
the
nerve-wracking
experience
of
writing
up
a
thesis
and,
as
opposed
to
a
nice
summary
here,
some
of
the
work
that
she's
working
on
in
the
interim
katy
did.
C
Yes,
I'll
quickly
walk
through
it.
I
think
I
created
some
compounds
in
the
first
term
like
until
december,
or
something
which
I
call
a
liberation
round
to
a,
and
I
I
think
I
spend
two
weeks
on
thinking
about
how
to
design
them
based
on
the
bar
analysis
of
dana's
elaborated
compounds
and
we
decided
to
synthesize
compounds
based
on
the
pipridine
core,
as
I
think
four
out
of
the
six
dual
inhibitors
have
that
same
core.
So
we
thought
it
was
a
good
starting
point.
C
So
we
focused
on
that
all
compounds
have
the
same
core
these
compounds.
I
took
them
to
oxford
and
we
tried
to
do
some
crystallography
with
them.
We
only
managed
to
do
soaking
and
I
think
the
results
are
not.
I
think,
they're
processed
by
laura,
but
I
don't
think
she
saw
any
anything.
So
that's
a
bit
sad,
but
yeah
then
in
the
meantime,
I
think
becca
did
her
dose
response
curse
on
the
dual
inhibitors,
and
out
of
that,
we
managed
to
see
that
the
compound
was
a
759.
C
I
guess
I
think,
of
elevation
round
one
had
a
good
ic50
value
of
less
than
40
micromolar.
I
think
it
was
21
point
something
so
that
looks
promising,
and
then
we
based
another
round.
D
C
Compounds
on
on
that
compound,
and
that's
what
I
call
elaboration
round-
2b
didn't
manage
to
purify
and
characterize
them
all.
So
I
think
it
will
continue
on
doing
that
and
after
that
is
finished,
I
think
we
can
send
the
whole
batch
for
more
crystallography,
the
enzymatic
essay
and
scr.
C
Yes,
that's
correct.
Some
are
already
purified
ones,
but
there
are
some
more
impurities
that
we
have
to
get
rid
of.
The
last
two
orange
ones
need
the
first
purification
as
well,
so
time
wise.
I
don't
really
know
how
long
that
takes
at
work
a
little
bit
faster
than
me,
though,.
A
All
right,
ed
anything
you
had
that
you're
you're
on
the
case
for
these
molecules.
A
A
Great
yeah,
I
mean
that
would
make
a
lot
of
sense,
because
that's
what
we've
we're
basing
this
on
right
is
is
becca's
original
experiment,
so
that
makes
a
lot
of
sense.
Spr,
I
guess
is,
is
doesn't
use
very
much
protein.
Is
it
fine
to
also
try
and
schedule
them
for
analysis
in
that?
If
that's
not
going
to
be
too
time
consuming.
G
We
we
can
do
spr,
but
I
would
do
with
more
compounds
to
because
this
is
a
problem
with
this
with
a
shortage
of
sensors,
so
we
need
to
be
smart
of
how
many
sensors
we
use.
So
when
we
get
the
compounds
from
the
competition,
I
can
test
many
other
compounds
as
well.
G
A
And
then
I
guess
you
know
the
the
issue
with
this
always
was
that
we
had
the
inhibition
data
from
becca's
experiments,
but
we
didn't
have
any
crystallography
with
these
compounds.
Of
course
that's
what
we're
aiming
for.
So
I
guess
I
mean:
does
it
make
any
sense
to
try
and
do
crystallography
with
these,
given
that
we
haven't
had
any
luck
with
the
the
simpler
compounds?
Yeah.
G
Yeah
yeah,
we
can,
I
don't
know
how
much
related
are
these
two
catalyst
compounds.
She
already
tried
some
soaking
on
mu
d
and
mu
e,
but
I
couldn't
see
any
any
components:
bond
on
the
data
that
was
collected.
A
Right
so
I
I
think
I
remember
from
the
last
just
looking
at
the
recording
earlier
that
there
was
some
discussion
about,
including
in
those
trials
uma
adp
things
like
that.
I
I
guess
I'm
wondering:
if
do
you
feel
as
though
you
want
to
try
and
optimize
the
the
soak
before
you
look
at
these
next
compounds,
is,
is
that
the
order
of
events.
G
We
already
try
with
some
of
some
compounds
from
cattle.
Well
as
she
did
it
when
she
was
in
diamond
with
lisbeth,
and
I
was
also
well-
I'm
also
trying
to
optimize
that
condition
to
do
soaking
on
the
more
compressed
conformation.
But
I
don't
have
more
updates
on
that,
because
it's
not
optimizing
as
well.
So.
F
G
H
B
A
J
F
J
J
I
C
Yeah
the
log
p,
except
for
one
compound,
I
think
the
c
log
p
is
below
three
and
they're.
Quite
when
I
try
to
dissolve
them
in
dtm
or
methanol,
it
looks
fine,
I
don't
dmso,
I
think
the
ones
I
took
to
oxford.
They
all
dissolved
in
dmso.
So
I
think
that's
actually
fine.
A
A
A
Submitting
the
exams
and
stuff
so
she
may
not
see
a
lot
of
her
on
on
the
website
in
the
next
few
weeks,
but
hopefully
we'll
get
some
nice
data
that
you
can
include
in
the
thesis.
A
All
right,
and
just
while
we're
on
the
same
page
eugene
did
you
want
to
just
quickly
update.
I
think
we
can
leave
all
the
stuff
to
do
with
the
shopping
list
compounds
which
we
are
looking
at,
but
I
guess
just
a
just
a
one-minute
update
on
where
you
are,
with
the
crucial
synthesis
of
the
amine
compound
they're
split
without
the
bot
group.
K
For
the
for
the
first
hd595
synthesis,
I
think
I've
updated
loss,
so
I
use
that
optimum
condition
apply
that
condition
to
to
the
to
the
next
reaction,
with
the
block
with
bulk
on
the
starter
material,
but
that
reaction
turned
out
to
be
too
harsh.
K
So
all
my
products
and
starting
materials
deteriorated
during
the
process,
so
I
started
to
use
the
lcms
monitoring
every
five
minutes
just
to
carefully
handle
this
reaction,
and
eventually
I
got
a
the
condition
should
be
limited
to
30
minutes
on
a
150
celsius,
degree
microwave.
K
So
everything
else
remains
the
same
as
the
sa
595
reaction,
so,
but
just
to
limit
the
time
to
30
minutes,
that's
it
and
the
separation
is
ongoing.
I
need
for
characterization-
and
this
is
a
new
compound
and
about
the
second
bullet
points.
I
think
this
is
something
that
we
need
help
from
young
because
because
I
think
peter
didn't
finish
it
I
haven't
got
the
results
afterwards.
K
A
K
Of
doing
this
is
because
we
want
to
see
how
how
this
double
two
product
was
overlaying
with
the
a0595
to
see
if
the
key
interactions
are
the
same
and
yeah
so
just
want
to
see
how
the
interactions
are
going
with
the
residues
of
these
ac
series
of
compounds
for
behaving
in
a
similar
way,
and
also
this
compound
has
a
positive
control.
A
K
We
haven't
got
any
data,
we
haven't,
got
any
data
from
from
peter
but
young.
Previously
I
only.
B
K
We
only
had
a
five-minute
video
video
zoom
zoom
meeting
with
peter,
and
he
only
briefly
showed
me
the
precision
of
this
compound
in
the
pocket.
Then
I
haven't
got
any
other
data
from
since
then
yeah
last
year.
L
D
L
A
I
think
on
action,
trackers
get
get
bigger
as
time
goes
by
it's
weird
all
right,
so
I
I
guess
there
are
some
other
key
things
from
last
time
I
mean
we've
we've,
so
we've
covered
some
of
the
chemistry
here
and
we
we've
covered
some
of
the
stuff
to
do
with
what
we're
going
to
do
with
these
other
compounds.
A
Here
there
is
still
an
action
on
me
to
follow
up
with
the
atomwise
guys
about
the
nature
of
their
compounds
and
and
and
where
they
found
they're
weighing
on
us
to
provide
them
with
a
description
of
exactly
what
happened
and
and
where
the
contents
are
and
all
the
data
we've
given
them
all
the
links,
but
they
still
wanted
a
description
of
exactly
what
we're
talking
about.
A
It
appeared
from
our
call
that
the
the
predictions
of
the
compounds
were
was
slightly
fortuitous
in
the
sense
that
they
they
had
predicted
compounds
to
bind
and
and
their
binding
better
because
of
the
the
change
in
structure
of
the
protein
when
when
the
binding
took
place,
but
we
we
need
to
provide
them
with
accurate
information,
so
they
can
give
us
their
final
analysis
and
potentially
suggest
some
other
compounds,
so
that
stuck
with
me
at
the
moment,
I'm
afraid-
and
I
haven't-
I
haven't
seen
that
through
and
then
so
before.
A
We
we
get
off
the
subject
of
the
crystallography
laura.
I
just
wanted
to
give
you
a
chance
to
say
anything.
You
wanted
to
about
anything
more.
You
may
have
done
or
lisbet
about
the
the
assays
to
try
and
get
structures
crystallized
with
with
small
molecules
bound
to
the
circling
experiments.
Are
there
any
updates?
You
need
to
provide
on
that
or
is
it?
Is
it
work
ongoing.
M
No,
so
all
I
basically
did
was
when
kato
was
here.
Have
her
screen
a
lot
of
core
screens
trying
to
find
it.
There
was
other
crystal
forms
or
anything
that
would
work
better
but
past.
All
the
data
seems
that
we
didn't
actually
manage
to
get
anything
else
better
than
what
you
already
have
it's
a
bit
sad,
okay,.
A
A
A
You
and
I
seem
to
remember
there
was
some
action
I
think
on
laura
again.
You
seem
to
be
getting
the
malt
today
about
shipping
some
uma
to
ssgcid
in
seattle.
G
F
Can
we
just
go
through
our
freezer
cupboards
and
pull
out
whatever
we
have,
and
rather
than
waiting.
G
Yeah
we
can
do
that,
I
would
it
be
okay,
one
or
two
milligrams.
I
think
we're
talking
about
two
milligrams.
F
Let's
see
if
we
can
get
that,
what
does
it
tuesday
see
if
we
can
get
it
posted
this
week?.
G
F
A
F
Just
enzymologist
in
the
shadows
there.
A
You
go
hi
adrian
hi.
I
just
watched
the
recording
from
last
time
very
interesting
data
you
were
showing
did
you
want
to
have
any
updates
today,
I'll.
A
A
All
right
great-
and
I
think
you
were
also
talking
so
you're
talking
about-
I
mean.
Obviously
I
see
50
values
of
all
compounds
and
whether
they
were
atp
competitive.
Is
that
still
an
up-to-date
aim?
Yes,
it
is
yeah,
okay,
great
just
for
from
what
you
were
talking
about.
Last
time
it
looked
like
you've,
measured
a
bunch
of
compounds.
Do
you
know
how
roughly,
how
far
through
that
sort
of
compounds
you
are,
I'm
sorry
how
what
how
far
through
the
set
you
are
so
of
the
total?
How
much
of
how
much
has
been
evaluated.
A
H
The
moment
incompletion
called
allogalactiii
and
something
like
around
and
we've
just
taken
the
algolactoid
hips
and
they've
characterized
those
with
the
other
ligases
at
the
moment
and
then
we'll
go
once
we're
once
we're
happy
with
the
performance
to
stop
downstairs,
then
we're
going
to
basically
go
and
repeat
the
enemy
set
on
c
through
to
f,
okay,.
A
Okay,
so
from
memory,
it
was
the
compounds
that
joe
and
becca
designed
it
was
like.
600
compounds.
A
A
A
But
let
me
let
me
just
talk
about
this,
so
just
I
there
was
some
comment
about
compound
numbering
and
about
being
systematic,
and
there
was
also
a
compound
about
a
comment
about
wanting
to
retain
provenance
and
origin
of
compounds
which
totally
yeah
in
so
we
we
devised
the
systematic
numbering
system,
which
is
the
one
that's
shown
on
the
screen
here,
which
is
the
one
that's
used
in
the
database
of
osa
molecules
so
which
is
which
is
an
integer
plus
salt
form
and
plus
batch
number,
which,
which
is
fairly
standard.
A
And
of
course,
if
you
want
to
talk
about
a
compound,
you
just
use
the
number.
You
don't
have
to
use
this
massive
string,
but
to
be
systematic
about
it,
that
there
is
a
number
there,
but
there
it's
always
very
convenient
in
projects
like
this
to
have
another
parallel
code,
which
is
more
bespoke
and
which
can
be
used
to
show
provenance
in
in
open
source.
Malaria,
for
example,
we've
always
had
part
of
the
code
is
the
letter
which
indicates
the
city
where
the
molecule
came
from
just
to
try
and
get
that
idea
across.
A
Obviously,
besides
the
number,
the
public
nature
of
the
work,
we're
doing
so,
you
know
reports
and
lab
notebooks,
and
what
have
you
also
ensures
that
there's
no
contribution
which
is
made,
which
is
divorced
from
the
person
who's
made
it.
I
mean
it's
absolutely
essential
that
that
is
maintained.
A
F
A
A
A
Allocation
for
the
city-
oh
you
can
so
it
can
be
anything.
No.
No
so
so
the
number
here
is
is
where
there's
a
rule,
but
you
know
your
code,
your
internal
code,
I
mean
we,
you
know
in
the
lab
books
we
use
in
in
ucl.
We
have
codes
that
are
that
are
people's
initials,
and
then
you
know
the
reaction
number
and
the
attempt
number
and
blah
blah
blah.
If
you
have
a
library
of
molecules,
you
probably
have
your
own
numbering
already
like
diamond
and
worried.
J
It's
very
useful,
though,
if
you
tell
people
to
avoid
certain
characters
which
don't
necessarily
get
transferred,
you
know.
So
if
you
stick
to
alphanumeric
things
and
avoid
slashes
and
things
like
this,
because
some
systems
will
just
treat
them
as
arithmetic
operators
and
things
like
this,
it's.
A
By
the
people
who
know
much
more
about
this
than
I
do
like
chris,
for
example,
that
the
underscore
is
still
useful-
and
that
reminds
me
of
using
like
windows,
95
and
naming
files
with
underscore
so
it
doesn't
get
the
computer
doesn't
get
confused.
But
that
still
is
it's.
It's
unambiguous
and
useful
in
a
way
that
apparently,
a
hyphen
is
not
because
there
are
three
different
kinds
of
hyphens
that
you
can
use.
A
Right
and
spacers
are
a
no-no,
so
we
used
to
have
in
open
source
malaria
used
to
be
osm,
so
sometimes
then
there
was
a
space
there
and
it
was
like
no,
it's
it's
a
horror
apparently
according
to
the
chemical
magicians.
So
so
something
with
underscores
is
good
or
with
no
gaps
at
all
is
even
better,
but
then
sometimes
it's
more
difficult
to
pass
those,
but
in
your
yeah
in
your
local.
What's
the
word
synonyms
for
molecules
and
your
local
codes?
Yes,
as
chris
says,
if
you
can
avoid
spaces
and
other
ambiguous
characters,.
A
A
All
right
good,
so
those
were
the
main
things.
Oh
yes,
there
was
sorry
there
was
a
question
also
a
discussion
about
funding
mechanisms
which
was
very
interesting
I'll,
put
up
some
notes
about
that
when
I
managed
to
write
up
the
notes
from
from
last
time
in
in
last
time's
notes,
a
summary
of
the
meeting,
the
the
discussion
of
r21
seems
like
a
sensible
idea.
I
mean
you
know
chris
dowson
and
I
need
to
keep
an
eye
on
funding
mechanisms
over
here
too.
A
The
the
thing
that
was
mentioned
about
the
nyad
program
for
making
molecules
for
amr
yeah
I'll
put
a
link
to
that.
It's
the
cc4carbcollection.org
thing
which
I'll
put
a
link
to
it,
does
look
interesting,
and
I
meant
to
raise
out
a
previous
meeting
that
we
should
be
checking
that
out
as
a
potential
source
of
funds
and
what
was
the
other
thing
that
was
mentioned.
I
think
oh
yeah
and
then
the
carbex
idea.
I'd
agree
with
what
joe
said
last
time
that
we're
not
yet
in
the
in
the
zone
for
anything
like
that.
A
With
the
current
level
of
data,
you
know
as
as
always
we
we.
We
have
been
aiming
for
molecules
with
better
mic
values
before
we
go
for
funding,
but
but
certainly
for
carvex.
You
need
something
that's
much
more
advanced
than
we
have.
I
think
I'm
giving
a
talk
about
I'm
giving
a
talk
about
open
source
antibiotics
at
the
gordon
conference
on
antibacterials
in
july
at
the
end
of
july.
A
So
I'll
summarize
this
project
and
what
we're
doing-
and
there
are
some
really
interesting
people
going
to
that
who
are
from
funding
agencies
and
it's
going
to
be
good
to
talk
to
people
there
about
possibilities.
A
All
right,
those
were
the
big
things
I
think
from
last
time,
and
I
don't
think
we
need
to
dwell
on
anything
else,
because
I
think
everything
else
is
pretty
clear.
So
I
just
wanted
to
throw
it
open
to
anybody
else
to
talk
about
anything
that
we
haven't
yet
mentioned.
F
I
I
wrote
to
the
merc
open
source
people
sent
in
the
and
got
a
very
warm
response
from
them,
but
I
haven't.
I
haven't,
found
a
proper
response
saying:
yes,
you
can
have
the
compounds,
so
I'm
just
gonna
go
back
and
check
with
my
junk
mail.
A
Okay
is:
does
it
look
onerous.
F
Well,
the
the
the
the
form
I
filled
in
was
not
onerous
because
I'd
written
most
of
those
words
and
it
was
just
cut
and
paste
from
the
elf
actually
and
yeah.
No
and-
and
they
said
yes,
we're
very
enthusiastic
about
sport,
sporting
antibiotic
discovery,
and
that
was
the
last
email
I
got.
So
I
need
to
go
back
and
just
make
sure
I
haven't
got
another
one.
I've
lost
or.
A
Is
it
I'm
sorry
if
I
missed
this,
is
there
some
is?
Is
the
library,
unusual
and
and
or
large,
do
we
know
anything
about
the
composition.
F
I
can't
remember
what
the
composition
is,
but
it
comes
unfettered
ip
unfettered,
which
was
the
appealing
part
of
it.
A
N
Yeah,
I
don't
think
that
there
was
any
specific
details
on
the
website
in
terms
of
the
actual
contents
of
the
library.
It's
I
think
it's
just
made
up
of
their.
You
know.
In-House
research
compounds
that
they've
generated
for
other
programs
yeah
chris
we've
had
a
similar
collaboration,
also
asked
to
to
reach
out
for
this
library
for
kinetoclustered
diseases,
and
they,
when
they
got
that
reply
email,
they
attached
an
mta
to
it.
N
So
if
they
forgot
to
attach
the
the
mta,
maybe
that's
all
that
you
actually
need,
but
yeah
I
mean
it.
It
sounded
like
it
was
a
really
interesting
opportunity
in
terms
of
having
compounds
that
are
drug-like,
but
I
have
no
idea
what
the
actual
contents
of
the
library
looks
like.
A
Right,
a
quick
update
on
the
on
the
the
competition
that
we're
running
we've
so
yan
and
kasperstein
have
submitted
some
compounds
that
we
are
currently
that
ed
and
I
are
currently
working
on
about
whether
we
can
buy
or
make
two
other
inputs
have
come
in
from
two
new
participants.
A
So
we
need
to
look
at
those
two
and
they
came
in
just
in
the
last
24
hours
and
we'll
be
we're
expecting
some
more
and
we
just
need
to
think
about
how
we're
going
to
secure
these
molecules
as
quickly
as
we
can.
So.
These
are
all
using
so-called
generative
methods
in
ai,
well,
to
the
extent
that
it's
possible
for
the
entrance
to
use
those
methods
they're
using
them,
and
we
may
get
some
interesting
suggestions.
A
Let's
see
we're
going
to
try
and
get
them
as
quickly
as
possible,
so
that
we
can
send
them
to
to
laura
for
evaluation,
but
we'll
keep
you
all
posted
and
we're
getting
we're
starting
to
get
the
inputs
now,
which
is
good.
We
have
reached
out
in
a
targeted
way
to
a
bunch
of
companies
working
in
this
area
and
we're
going
to
try
and
do
the
same
with
academic
groups
now
as
well.
F
Yeah
thanks
laurie
I've
just
found
the
email,
but
our
warwick
mail
protection
system
has
managed
to
delete
the
attachment.
So
I
read
it:
oh
boy,
and
so
I'm
gonna,
I'm
gonna
reply
to
that
may
use
my
private
email
address
or
something
yeah
have
another
route
yeah
thanks
for
that.
A
Okay,
good,
I
have
nothing
else
so.
L
So
I
guess
I'll
I'll
I'll
pipe
up
here,
so
chris's
group
has
done
a
fantastic
job.
You
know
last
whatever
it's
been
six
months
a
year,
getting
the
biochemical
sa
in
place.
So
that
really
seems
to
be
in
a
great
great
position
right
now,
so
I
think
the
the
obvious
struggle-
and-
and
this
is
not
meant
to
anyway-
the
obvious
right
now
we
need
we
need
crystallography.
We
need
to
get
crystal
structures
for
these
compounds.
I
think
that's.
L
Really
essential,
probably
for
any
kind
of
grant
funding,
and
I'm
just
wondering
if
there's
worthwhile
for
a
kind
of
special
meeting
or
brainstorming
session
to
kind
of
go
through.
L
What's
been
done
and
and
and
maybe
some
you
know,
thoughts
about
what
really
artists
I
know
laura,
I
know
you're
working
hard
on
this.
I'm
this
is
not
meant
to
be.
This
is
not
trying
not
to
be
monday
morning
where
you
call
monday
morning,
quarterbacking
here,
but
just
in
terms
of
I
think
this
is
the
nut
we
have
to
crack
in
terms
of
crystallography
and
figuring
out.
L
You
know
what
what
are
the
various
ways
and
what
resources
we
have
to
to
try
to
to
make
to
make
progress
there,
because
I
think
that
at
least
from
my
perspective,
I
don't
think
we
can
get
at
least
any
nih
funding,
without
probably
crystal
structures
of
some
of
these
compounds.
L
So
anyway,
just
the
thought
of
you
know.
Is
it
worthwhile
having
any
kind
of
a
crystallography
summit
or
something
that
where
the
experts
here
get
together
and
try
to
see,
if
you
know
what
stones
have
been
left
unturned,
maybe
put
it
that
way.
A
A
I
suppose
in
advance
of
that
meaning
it
would
be.
I
mean
again
it's
it's.
I
don't
want
to
put
too
many
tasks
on
people,
but
if
we
could
somewhere
assemble
a
very
short
description
of
exactly
what's
been
tried
so
far
that
might
help
us
in
determining
where
the
gaps
might
be.
A
If
people
are
willing
to
to
put
together
a
few
slides
that
we
can
have
a
look
at
to
to
be
clear
about
that,
because
we
mentioned
in
the
meetings
and-
and
we
try
and
take
notes
and
things,
but
it'd
be
good
just
to
go
through
the
kind
of
grid
of
different
proteins
and
where
they
come
from
and
what's
been
attempted.
That
would
be
pretty
useful.
L
Actually,
one
thoughts
just
came
to
mind
almost
even
so,
even
if
you
know
we
do
the,
I
can
never
say
it.
The
galactic
system,
your
d,
granted
it's
not
a
gram
negative,
but
I'm
not,
I
don't
know,
do
you
think,
that's
any
more
robust
to
potentially
try
some
of
the
the
hits
against
that
system.
I
mean.
Obviously
we
want
to
invite
ideally
get
something
against
pseudomonas
or
e
coli
or
acetobacter
would
be
the
preferred
species.
L
But
if
we
had
the
you
know,
if
you
have,
the
biochemical
data
to
you
know
show
that
you're
hitting
you
know
several
of
the
gram
negatives
as
long
as
well
as
like
community
grace
structure,
species.
G
L
Okay,
all
right
again,
those
are
the
the
the
we
call,
the
practicalities.
G
L
I
don't
know
no.
I
was
just
trying
to
say
that
sometimes
you
know
if
we
could
get
if
there's,
if
there's
an
other
cis
ligase
species,
that
was
close
enough.
That
made
sense
that
you
thought
you
could
get
better.
You
know
you
might
be
more
robust
in
terms
of
crystallography.
That
was
just
the
thought.
H
G
F
Just
as
an
fyi
joe
we've,
when
we
actually
found
the
a
galactic
eye
system,
previous
postdoc,
don
bellini
must
have
looked
at
about
15,
others
as
well,
and
so
that
was
the
best
of
a
bad
job.
L
A
A
All
right
good,
I
can,
I
can
send
around
some
times
and
see
if
we
can
meet
up
at
some
some
useful
time.
A
L
A
L
L
L
It's
like
it's
the
version
of
second-guessing
american
football
players
and
that's
that's
what
it's
about.
F
A
All
right
great,
thank
you
for
that
joke,
good
point
and
good
idea
all
right.
If
there's
nothing
else,
then
we
can
end
at
a
quarter
too,
very
nice
to
see
everybody.
Thank
you
very
much
for
coming
along
I'll
put
up
some
notes
online,
and
our
next
meeting
is
again
the
second
tuesday
next
month,
but
we'll
have
our
you
know.
Crystallography
soak
in
in
towards
the
end
of
the
month
sounds
good.